Latest Viropro Inc (VPRO) Headlines Psoriatic Art
Post# of 37
Posted On: 03/12/2014 1:40:19 AM
Latest Viropro Inc (VPRO) Headlines
Psoriatic Arthritis - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ss7tp6/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H2 2013" report to their offering. 'Psoriatic Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. Scope - A snapshot of the global therapeutic scenario for Psoriatic Arthritis. - A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psoriatic Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. Johnson & Johnson Amgen Inc. Eli Lilly and Company Celltrion, Inc. Biocon Limited Pfizer Inc. UCB Group Celgene Corporation Biovitrum AB Panacea Biotec Limited Viropro Inc. Alder Biopharmaceuticals Inc. Coronado Biosciences, Inc. Covagen AG Shanghai Celgen Bio-Pharmaceutical Co., Ltd. Bio Sidus S.A. For more information visit http://www.researchandmarkets.com/research/ss7tp6/psoriatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.
Psoriatic Arthritis - Pipeline Review, H2 2013
M2 - Mon Oct 14, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ss7tp6/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H2 2013" report to their offering. 'Psoriatic Arthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Psoriatic Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis. Scope - A snapshot of the global therapeutic scenario for Psoriatic Arthritis. - A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Psoriatic Arthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Alcon, Inc. Johnson & Johnson Amgen Inc. Eli Lilly and Company Celltrion, Inc. Biocon Limited Pfizer Inc. UCB Group Celgene Corporation Biovitrum AB Panacea Biotec Limited Viropro Inc. Alder Biopharmaceuticals Inc. Coronado Biosciences, Inc. Covagen AG Shanghai Celgen Bio-Pharmaceutical Co., Ltd. Bio Sidus S.A. For more information visit http://www.researchandmarkets.com/research/ss7tp6/psoriatic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
PR Newswire Europe - Mon Feb 25, 9:03AM CST
Viropro, Inc. and Oncobiologics, Inc. announced today the signing of a biosimilar collaboration agreement. Under the agreement, Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging market countries (excluding China). Viropro will have exclusive commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Penang, Malaysia Alpha Biologics biomanufacturing subsidiary. The alliance will seek regional partners to drive commercialization.
(0)
(0)Viropro Inc (VPRO) Stock Research Links
Scroll down for more posts ▼